Engene (ENGN) announces CMO resignation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
enGene Announces the Resignation of its Chief Medical Officer
June 4, 2025 8:30 AM EDTBOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthis resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Pruthis responsibilities to the Companys other urology and clinical experts. The Company thanks Dr. Pruthi for his dedication and service and wishes him the best in his future... More



